Association of circulating TNF-alpha and IL-6 with ageing and parkinsonism.
about
Eradication of Helicobacter pylori infection improves levodopa action, clinical symptoms and quality of life in patients with Parkinson's diseaseDegeneration of Dopaminergic Neurons Due to Metabolic Alterations and Parkinson's DiseaseBrain-gut-microbiota axis in Parkinson's diseaseInsights into Neuroinflammation in Parkinson's Disease: From Biomarkers to Anti-Inflammatory Based TherapiesThe role of the immune system in neurodegenerative disorders: Adaptive or maladaptive?Vaccination strategies for Parkinson disease: induction of a swift attack or raising tolerance?The IkappaB kinase family phosphorylates the Parkinson's disease kinase LRRK2 at Ser935 and Ser910 during Toll-like receptor signalingGenomic determinants of motor and cognitive outcomes in Parkinson's diseaseLeukocyte-subset counts in idiopathic parkinsonism provide clues to a pathogenic pathway involving small intestinal bacterial overgrowth. A surveillance study.The relation between DNA methylation patterns and serum cytokine levels in community-dwelling adults: a preliminary study.Association of NQO1 and TNF polymorphisms with Parkinson's disease: A meta-analysis of 15 genetic association studiesDifferential effect of Helicobacter pylori eradication on time-trends in brady/hypokinesia and rigidity in idiopathic parkinsonism.Apoptosis modulators in the therapy of neurodegenerative diseases.Non-motor symptoms in patients with Parkinson's disease - correlations with inflammatory cytokines in serumThe endotoxin-induced neuroinflammation model of Parkinson's disease.Central pathways causing fatigue in neuro-inflammatory and autoimmune illnesses.Systemic inflammation (Interleukin 6) predicts all-cause mortality in men: results from a 9-year follow-up of the MEMO StudyTranscription factor myocyte enhancer factor 2D regulates interleukin-10 production in microglia to protect neuronal cells from inflammation-induced death.Peripheral aetiopathogenic drivers and mediators of Parkinson's disease and co-morbidities: role of gastrointestinal microbiota.Immune aging, dysmetabolism, and inflammation in neurological diseases.NOP Receptor Ligands as Potential Agents for Inflammatory and Autoimmune Diseases.Potential role of gut microbiota and tissue barriers in Parkinson's disease and amyotrophic lateral sclerosis.Imaging Striatal Microglial Activation in Patients with Parkinson's Disease.Markers of inflammation in prevalent and incident Parkinson's disease in the Cardiovascular Health StudyTreatment for Helicobacter pylori infection and risk of Parkinson's disease in Denmark.Impact of aging on pulmonary responses to acute ozone exposure in mice: role of TNFR1.Interleukin-6 May Contribute to Mortality in Parkinson's Disease Patients: A 4-Year Prospective StudyPeripheral chemo-cytokine profiles in Alzheimer's and Parkinson's diseasesProteolytic activation of proapoptotic kinase protein kinase Cδ by tumor necrosis factor α death receptor signaling in dopaminergic neurons during neuroinflammationEvaluation of systemic markers of inflammation in atomic-bomb survivors with special reference to radiation and age effects.The microRNA miR-181c controls microglia-mediated neuronal apoptosis by suppressing tumor necrosis factor.Bent out of shape: α-Synuclein misfolding and the convergence of pathogenic pathways in Parkinson's disease.Impact of intravenous immunoglobulin on the dopaminergic system and immune response in the acute MPTP mouse model of Parkinson's diseaseAn integrated view of oxidative stress in aging: basic mechanisms, functional effects, and pathological considerations.Leptin levels recover normally in healthy older adults after acute diet-induced weight lossBlood profile holds clues to role of infection in a premonitory state for idiopathic parkinsonism and of gastrointestinal infection in established diseaseDefining the contribution of neuroinflammation to Parkinson's disease in humanized immune system mice.Pharmacological therapy in Parkinson's disease: focus on neuroprotection.Peripheral biomarkers of Parkinson's disease as early reporters of central neurodegeneration.Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy?
P2860
Q21131896-C3A87708-045A-4E9F-AF44-7DF04E6AAEFCQ26750370-DB139CB5-E438-455A-9D09-62E2CCCEC869Q26784403-98F47C78-EAE1-41B7-9DF3-6207F7C6A4C3Q26795984-CC1FAC86-B7B9-4794-B7D2-C15AA681B290Q26861263-0CB97A12-257D-445E-A01E-02D39B058993Q27015811-2CC9870D-DB71-45DB-996B-A52C42BD4D27Q28480459-05903591-5F0D-45C9-B7D0-26110BE4E406Q28943408-D728324E-129B-4C52-A18F-16040DDA0FBAQ30528442-F216F6A1-6433-4958-946C-1FFA80BB5438Q33823413-259D8D9B-E2C9-4422-9348-99D833CD2C44Q33932167-28F75E7F-7ABB-4326-8082-5950C938E644Q34032330-7CB0F8F8-2316-4AFB-85C5-09E7B2DB0FAEQ34074800-B37C3898-1F9F-47C3-8C0F-A0369C41ACFFQ34452085-C477DB62-C745-46CF-BD09-D564435F366AQ34557246-E396E98E-FF8D-438A-91E5-7781C26FA75FQ35059951-5E61CC8B-D305-49B0-ABB1-AECAA6296F60Q35080224-FD84AC6A-4C6E-457A-811F-3EA5731158F5Q35118158-BA59D2FF-E108-4556-9A76-90C0463096B6Q35669153-EEF2F7A0-786A-4BBD-8FBF-C142BC57B4A0Q35677347-25B4DD9A-B299-4A11-8BEB-2C8572322991Q35708377-596609B6-0FE1-4369-8180-223C88A9E518Q35779264-AB5AD80C-BCF4-4446-B16F-0B4FF1B55511Q35779298-98FC7CBC-7C4D-440C-B9C7-ECC5370D341CQ35785450-DE4781F1-B3B9-472F-BABD-7235D68790C6Q35899185-EF6EA226-DA6E-47C0-8BA4-05E49AE94270Q35986305-01813702-6F86-4E4E-9DBB-7A12699C81B0Q36006272-A61760B0-9EAA-46A6-AD94-858BB3C1E51DQ36023238-099E9ED1-D73F-4810-8979-E979EE5E1FCCQ36165760-CFAB11F5-AC4B-4152-ADD5-84CC8BDD7581Q36329753-92FBA7D1-7337-41CE-BEFD-4FD9065D4870Q36369776-96C3D718-1331-45C3-9F07-15DD2864D96FQ36373170-3E29BD7D-CC2F-4338-8A8D-E3101D794103Q36462680-FA860B2E-903D-4575-A93D-E5DFBDA2C3A3Q36569112-B0E26DF1-18E3-4900-BA26-6912D504301EQ37315609-BB03334C-D6FF-4D8F-975C-785A64E032E4Q37483107-DD3FCD04-2586-4389-AA2F-7325BB9ABA0DQ37642992-54AAE331-C409-4706-B3C2-15E345599974Q37741285-A786AF54-24C5-4D05-9D93-B83A42E51FEFQ37755118-8988D3DA-4750-42BA-BB3C-123612E1D3E6Q37878285-DDCF99D0-1254-4834-8933-7BD7B0607148
P2860
Association of circulating TNF-alpha and IL-6 with ageing and parkinsonism.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh
1999年學術文章
@zh-hant
name
Association of circulating TNF-alpha and IL-6 with ageing and parkinsonism.
@en
Association of circulating TNF-alpha and IL-6 with ageing and parkinsonism.
@nl
type
label
Association of circulating TNF-alpha and IL-6 with ageing and parkinsonism.
@en
Association of circulating TNF-alpha and IL-6 with ageing and parkinsonism.
@nl
altLabel
Association of circulating TNF-α and IL-6 with ageing and parkinsonism
@en
prefLabel
Association of circulating TNF-alpha and IL-6 with ageing and parkinsonism.
@en
Association of circulating TNF-alpha and IL-6 with ageing and parkinsonism.
@nl
P2093
P1476
Association of circulating TNF-alpha and IL-6 with ageing and parkinsonism.
@en
P2093
P356
10.1111/J.1600-0404.1999.TB00721.X
P407
P577
1999-07-01T00:00:00Z